The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Yung-Jue Bang
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme (Inst)
 
Charles S. Fuchs
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Lilly; Macrogenics; MedImmune; MedImmune; Merck; Momenta Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda; Vertex
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Bayer Yakuhin
 
Uma Kher
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Baohoang Lam
Employment - Merck
 
Minori Koshiji
Employment - Merck
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)